Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Debt (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Total Debt data on record, last reported at $13.5 million in Q3 2025.

  • For Q3 2025, Total Debt fell 52.17% year-over-year to $13.5 million; the TTM value through Sep 2025 reached $13.5 million, down 52.17%, while the annual FY2024 figure was $24.6 million, 16.23% down from the prior year.
  • Total Debt reached $13.5 million in Q3 2025 per RANI's latest filing, down from $17.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $29.5 million in Q2 2024 and bottomed at $30000.0 in Q2 2022.
  • Average Total Debt over 5 years is $20.3 million, with a median of $26.5 million recorded in 2024.
  • Peak YoY movement for Total Debt: crashed 95.07% in 2021, then soared 97450.0% in 2023.
  • A 5-year view of Total Debt shows it stood at $126000.0 in 2021, then soared by 23034.13% to $29.1 million in 2022, then rose by 0.8% to $29.4 million in 2023, then decreased by 16.23% to $24.6 million in 2024, then crashed by 45.0% to $13.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $13.5 million in Q3 2025, $17.2 million in Q2 2025, and $20.9 million in Q1 2025.